Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPR · Real-Time Price · USD
35.86
+2.35 (7.01%)
At close: Aug 14, 2025, 4:00 PM
36.94
+1.08 (3.01%)
After-hours: Aug 14, 2025, 5:37 PM EDT
Monopar Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts that cover Monopar Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $62, which forecasts a 72.89% increase in the stock price over the next year. The lowest target is $40 and the highest is $76.
Price Target: $62 (+72.89%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Monopar Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
---|---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
Buy | 2 | 2 | 2 | 2 | 3 | 3 |
Hold | 0 | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 5 | 6 | 6 | 6 | 7 | 7 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Chardan Capital | Chardan Capital | Strong Buy Maintains $60 | Strong Buy | Maintains | $60 | +67.32% | Aug 13, 2025 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $74 | Buy | Initiates | $74 | +106.36% | Jul 7, 2025 |
Chardan Capital | Chardan Capital | Strong Buy Initiates $60 | Strong Buy | Initiates | $60 | +67.32% | Jun 23, 2025 |
Jones Trading | Jones Trading | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Apr 2, 2025 |
HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +11.54% | Apr 1, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
969.00K
EPS This Year
-2.15
from -4.11
EPS Next Year
-3.57
from -2.15
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | n/a | 4.0M | 44.0M | ||
Avg | n/a | 969,000 | 19.9M | ||
Low | n/a | n/a | 7.2M |
Revenue Growth
Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | 4,440.2% | ||
Avg | - | - | 1,955.4% | ||
Low | - | - | 646.2% |
EPS Forecast
EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | -1.74 | -2.00 | 0.63 | ||
Avg | -2.15 | -3.57 | -0.47 | ||
Low | -2.51 | -5.89 | -1.49 |
EPS Growth
EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.